WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Bioanalytical Systems, Inc. About Glucovance (Glyburide(Glibenclamide)-Metformin) without Rx (NASDAQ:BASI) has entered into an
agreement with PDS
Life Sciences (PDS) to fully upgrade its laboratory information
management system (LIMS) to Ascentos™. About Pamelor (Nortriptyline)
The new Ascentos software represents the next generation of preclinical
research LIMS and is a fully integrated software solution that includes
toxicology, clinical pathology, toxicokinetics and pathology modules
that streamline data management and reporting.
BASi will also implement the TranSEND™ solution as part of the
enhancements being made by the company. Buy Kamagra Soft (Sildenafil Citrate) The new automated software
converts study data to the new Standard for Exchange of Nonclinical Data
(SEND) format that will be required by the FDA beginning in December
2016. Buy Dermol with no Rx TranSEND
effectively aggregates and translates data from multiple LIMS to produce
one set of harmonized and validated SEND files as required by the FDA. Buy Women Pack-40 () with no prescription
With this sophisticated tool, BASi will now be able to provide SEND
study datasets that are ready for electronic data submission to the FDA
without any further processing by the client.
BASi President and CEO Jacqueline Lemke said, “Upgrading to PDS’
Ascentos and the addition of the TranSEND solution represent vital
enhancements to our IT infrastructure that will harmonize data
collection and reduce the time to complete a study and deliver our
report.”
Philip A. Buy Slippery Elm online Downing, vice president of preclinical services at BASi,
concluded, “Being able to provide the data in SEND-ready format will
shave weeks to months off of clients’ timelines since there is no need
to do the SEND conversion themselves.”
“We are very excited to expand our relationship with BASi because the
company has always been unique in having both sophisticated lab
instrumentation and preclinical research services. http://doctor-answers.blogspot.com/ Since PDS already has
extensive experience in SEND dataset conversion, we look forward to
helping BASi become one of the leaders in the CRO field regarding
electronic submission compliance. This capability will be a real value
added service for BASi clients,” said Sayed Badrawi, CEO of PDS Life
Sciences.
BASi expects final installation of the various modules to be completed
this summer with validation testing continuing throughout the rest of
the calendar year 2015 and full validation being completed well in
advance of the FDA-mandated deadline of December 2016.
About Bioanalytical Systems, Inc.
BASi™ is a pharmaceutical development company with over 40 years of
regulatory excellence in providing contract research services and
monitoring instruments to the world s leading drug development companies
and medical research organizations. The company focuses on developing
innovative services and products that increase efficiency and reduce the
cost of taking a new drug to market. Visit .BASinc.com
for more about BASi.
About PDS Life Sciences
For more than 30 years, PDS has provided intuitive data management
software and solutions for life sciences research and development
programs worldwide. Most of the world’s top 10 pharma companies rely on
PDS software, as do industry-leading CROs, chemical companies,
universities and regulatory agencies. The PDS software lineup is
centered on Ascentos™,
your integrated preclinical software solution, which is purpose-built to
support toxicology, clinical pathology, reproductive toxicology and
anatomic pathology. PDS also offers TranSEND™,
your complete FDA submission management solution, as well as powerful
bioinformatics analysis and other services. Learn more at pdslifesciences.com.
No comments:
Post a Comment